Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02446041 · ClinicalTrials.gov registry record
ICS/LABA Adherence and COPD Exacerbation
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 10,000
- Enrollment target
NCT02446041: Completed study, sponsored by AstraZeneca.
NCT02446041 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 10,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02446041 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 10,000 participants
- Enrollment target
Study Summary
The purpose of this retrospective, non-interventional sutdy is to compare the effectiveness of ICS/LABA combination therapy in the reduction of COPD exacerbations during the 12 months after initiation of therapy between COPD patients who are adherent to the index medication and those who are non-adherent.
Primary Outcome
Rate of COPD exacerbation occurring during the 12 months after therapy initiation.
Interventions
- OTHER Non-Interventional Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2015-05 |
| Est. Completion | 2015-10 |
What the finished NCT02446041 record still lists
NCT02446041 is an observational study that tracks outcomes without assigning an intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT02446041 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02446041 about?
NCT02446041 is a clinical study titled "ICS/LABA Adherence and COPD Exacerbation". The purpose of this retrospective, non-interventional sutdy is to compare the effectiveness of ICS/LABA combination therapy in the reduction of COPD exacerbations during the 12 months after initiation of therapy between COPD patients who are adherent to the index medication and those who are non-adh...
What is the current status of trial NCT02446041?
This trial is currently completed. The enrollment target is 10,000 participants. The study started on 2015-05. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02446041?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT02446041?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia